Hongbo Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hongbo Zheng has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Hong-Xiang Lou
Shandong University
8 shared publications Bin Sun
National Glycoengineering Research Center, Shandong University, Jinan 250100, China
4 shared publicationsWenqiang Chang
Department of Natural Product Chemistry, Key Lab of Chemical Biology of Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China
3 shared publicationsZhiyu Xie
Key Laboratory of Micro-Nano Materials for Energy Storage and Conversion of Henan Province, Institute of Surface Micro and Nano Materials, College of Chemical and Materials Engineering, Xuchang University, Xuchang 461002, China
3 shared publicationsHuiqing Yuan
Key Laboratory of Experimental Teratology of the Ministry of Education, Institute of Medical Sciences, The Second Hospital of Shandong University, Jinan 250013, China
2 shared publicationsJianbo Ji
Department of Natural Products Chemistry, Key Laboratory of Natural Products & Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China
2 shared publications
Latest Publications
- Top Cited Papers
- 5 December 2024
- Published by Springer Nature in Nature Energy
- Vol. 10 (1) , 90-100
Machine learning-accelerated discovery of heat-resistant polysulfates for electrostatic energy storage
- 5 December 2024
- Published by Springer Nature in Nature Energy
- Vol. 10 (1) , 90-100
Top Cited PapersMachine learning-accelerated discovery of heat-resistant polysulfates for electrostatic energy storage
- 3 October 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (19) , 13684-13704
Benzamidine Conjugation Converts Expelled Potential Active Agents into Antifungals against Drug-Resistant Fungi
Fungal infections present a growing global public health concern, necessitating the development of novel antifungal drugs. However, many potential antifungals, particularly the expelled potential active agents (EPAAs), are often underestimated owing to their limitations in cellular entry or expulsion by efflux pumps. Herein, we identified 68 EPAAs out of 2322 candidates with activity against a Candida albicans efflux pump-deficient strain and no inhibitory activity against the wild-type strain. Using a novel conjugation strategy involving benzamidine (BM) as a mitochondrion-targeting warhead, we successfully converted EPAAs into potent antifungals against various urgent-threat azole-resistantCandida strains. Among the obtained EPAA-BM conjugates, IS-2-BM (11) exhibited excellent antifungal activities and induced negligible drug resistance. Furthermore, IS-2-BM prevented biofilm formation, eradicated mature biofilms, and exhibited excellent therapeutic effects in a murine model of systemic candidiasis. These findings provide a promising strategy for increasing the possibilities of discovering more antifungals.
- 3 October 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (19) , 13684-13704
Benzamidine Conjugation Converts Expelled Potential Active Agents into Antifungals against Drug-Resistant Fungi
Fungal infections present a growing global public health concern, necessitating the development of novel antifungal drugs. However, many potential antifungals, particularly the expelled potential active agents (EPAAs), are often underestimated owing to their limitations in cellular entry or expulsion by efflux pumps. Herein, we identified 68 EPAAs out of 2322 candidates with activity against a Candida albicans efflux pump-deficient strain and no inhibitory activity against the wild-type strain. Using a novel conjugation strategy involving benzamidine (BM) as a mitochondrion-targeting warhead, we successfully converted EPAAs into potent antifungals against various urgent-threat azole-resistantCandida strains. Among the obtained EPAA-BM conjugates, IS-2-BM (11) exhibited excellent antifungal activities and induced negligible drug resistance. Furthermore, IS-2-BM prevented biofilm formation, eradicated mature biofilms, and exhibited excellent therapeutic effects in a murine model of systemic candidiasis. These findings provide a promising strategy for increasing the possibilities of discovering more antifungals.
- Open Access
- 26 September 2023
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 3 (10) , 2749-2762
Targeting GDP-Dissociation Inhibitor Beta (GDI2) with a Benzo[a]quinolizidine Library to Induce Paraptosis for Cancer Therapy
Inducing paraptosis, a nonapoptotic form of cell death, has great therapeutic potential in cancer therapy, especially for drug-resistant tumors. However, the specific molecular target(s) that trigger paraptosis have not yet been deciphered yet. Herein, by using activity-based protein profiling, we identified the GDP-dissociation inhibitor beta (GDI2) as a manipulable target for inducing paraptosis and uncovered benzo[a]quinolizidine BQZ-485 as a potent inhibitor of GDI2 through the interaction with Tyr245. Comprehensive target validation revealed that BQZ-485 disrupts the intrinsic GDI2-Rab1A interaction, thereby abolishing vesicular transport from the endoplasmic reticulum (ER) to the Golgi apparatus and initiating subsequent paraptosis events including ER dilation and fusion, ER stress, the unfolded protein response, and cytoplasmic vacuolization. Based on the structure of BQZ-485, we created a small benzo[a]quinolizidine library by click chemistry and discovered more potent GDI2 inhibitors using a NanoLuc-based screening platform. Leveraging the engagement of BQZ-485 with GDI2, we developed a selective GDI2 degrader. The optimized inhibitor (+)-37 and degrader 21 described in this study exhibited excellent in vivo antitumor activity in two GDI2-overexpressing pancreatic xenograft models, including an AsPc-1 solid tumor model and a transplanted human PDAC tumor model. Altogether, our findings provide a promising strategy for targeting GDI2 for paraptosis in the treatment of pancreatic cancers, and these lead compounds could be further optimized to be effective chemotherapeutics.
- 26 September 2023
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 3 (10) , 2749-2762
Open AccessTargeting GDP-Dissociation Inhibitor Beta (GDI2) with a Benzo[a]quinolizidine Library to Induce Paraptosis for Cancer Therapy
Inducing paraptosis, a nonapoptotic form of cell death, has great therapeutic potential in cancer therapy, especially for drug-resistant tumors. However, the specific molecular target(s) that trigger paraptosis have not yet been deciphered yet. Herein, by using activity-based protein profiling, we identified the GDP-dissociation inhibitor beta (GDI2) as a manipulable target for inducing paraptosis and uncovered benzo[a]quinolizidine BQZ-485 as a potent inhibitor of GDI2 through the interaction with Tyr245. Comprehensive target validation revealed that BQZ-485 disrupts the intrinsic GDI2-Rab1A interaction, thereby abolishing vesicular transport from the endoplasmic reticulum (ER) to the Golgi apparatus and initiating subsequent paraptosis events including ER dilation and fusion, ER stress, the unfolded protein response, and cytoplasmic vacuolization. Based on the structure of BQZ-485, we created a small benzo[a]quinolizidine library by click chemistry and discovered more potent GDI2 inhibitors using a NanoLuc-based screening platform. Leveraging the engagement of BQZ-485 with GDI2, we developed a selective GDI2 degrader. The optimized inhibitor (+)-37 and degrader 21 described in this study exhibited excellent in vivo antitumor activity in two GDI2-overexpressing pancreatic xenograft models, including an AsPc-1 solid tumor model and a transplanted human PDAC tumor model. Altogether, our findings provide a promising strategy for targeting GDI2 for paraptosis in the treatment of pancreatic cancers, and these lead compounds could be further optimized to be effective chemotherapeutics.
- Open Access
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (50) , eadd5366
Inhibition of fungal pathogenicity by targeting the H 2 S-synthesizing enzyme cystathionine β-synthase
The global emergence of antifungal resistance threatens the limited arsenal of available treatments and emphasizes the urgent need for alternative antifungal agents. Targeting fungal pathogenic functions is an appealing alternative therapeutic strategy. Here, we show that cystathionine β-synthase (CBS), compared with cystathionine γ-lyase, is the major enzyme that synthesizes hydrogen sulfide in the pathogenic fungus Candida albicans . Deletion of CBS leads to deficiencies in resistance to oxidative stress, retarded cell growth, defective hyphal growth, and increased β-glucan exposure, which, together, reduce the pathogenicity of C. albicans . By high-throughput screening, we identified protolichesterinic acid, a natural molecule obtained from a lichen, as an inhibitor of CBS that neutralizes the virulence of C. albicans and exhibits therapeutic efficacy in a murine candidiasis model. These findings support the application of CBS as a potential therapeutic target to fight fungal infections.
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (50) , eadd5366
Open AccessInhibition of fungal pathogenicity by targeting the H 2 S-synthesizing enzyme cystathionine β-synthase
The global emergence of antifungal resistance threatens the limited arsenal of available treatments and emphasizes the urgent need for alternative antifungal agents. Targeting fungal pathogenic functions is an appealing alternative therapeutic strategy. Here, we show that cystathionine β-synthase (CBS), compared with cystathionine γ-lyase, is the major enzyme that synthesizes hydrogen sulfide in the pathogenic fungus Candida albicans . Deletion of CBS leads to deficiencies in resistance to oxidative stress, retarded cell growth, defective hyphal growth, and increased β-glucan exposure, which, together, reduce the pathogenicity of C. albicans . By high-throughput screening, we identified protolichesterinic acid, a natural molecule obtained from a lichen, as an inhibitor of CBS that neutralizes the virulence of C. albicans and exhibits therapeutic efficacy in a murine candidiasis model. These findings support the application of CBS as a potential therapeutic target to fight fungal infections.
- Open Access
- 1 July 2021
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 804 (4) , 042065
Analysis of Air Pollution Influencing Factors of PM2.5 Secondary Particles by Random Forest
Aiming at figuring out the influencing factors of PM2.5 secondary particles, there is a new way of using random forest model to handle it. Compared with using correlation to measure the relationship between various single factors and PM2.5, in this paper, the random forest can comprehensively consider the overall factors including meteorological and other air pollution factors. In a case of Dalian, the results show that NO2 is the primary factor of PM2.5 in the first and fourth quarter, and O3 is the primary factor in the third quarter. From the perspective of big data, this is a persuasive way to provide reference for PM2.5 pollution control in different quarters.
- 1 July 2021
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 804 (4) , 042065
Open AccessAnalysis of Air Pollution Influencing Factors of PM2.5 Secondary Particles by Random Forest
Aiming at figuring out the influencing factors of PM2.5 secondary particles, there is a new way of using random forest model to handle it. Compared with using correlation to measure the relationship between various single factors and PM2.5, in this paper, the random forest can comprehensively consider the overall factors including meteorological and other air pollution factors. In a case of Dalian, the results show that NO2 is the primary factor of PM2.5 in the first and fourth quarter, and O3 is the primary factor in the third quarter. From the perspective of big data, this is a persuasive way to provide reference for PM2.5 pollution control in different quarters.
- 1 October 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 158, 767-780
Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect
- 1 October 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 158, 767-780
Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect
- 1 August 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (14) , 4320-4328
Terpenoids with vasorelaxant effects from the Chinese liverwort Scapania carinthiaca
- 1 August 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (14) , 4320-4328
Terpenoids with vasorelaxant effects from the Chinese liverwort Scapania carinthiaca
- 4 August 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (16) , 7166-7185
Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide
Protease-activated receptor-1 (PAR1), a G-protein-coupled receptor, plays a critical role in thrombin-mediated platelet aggregation. It is regarded as a promising antithrombosis target that is unlikely to result in bleeding. Here, we describe the synthesis of a series of novel PAR1 antagonists by borrowing the chiral fragment of andrographolide, an easily accessible natural molecule from Andrographis paniculata, to produce natural product/synthesis hybrids. An in vitro PAR1 inhibition assay and an in vivo pharmacokinetic profile led to the identification of compound 39 as the best PAR1 inhibitor. The further in vitro and ex vivo antiplatelet aggregation assays of compound 39 indicated that compound 39 was a potent antiplatelet agent. In addition, this compound is metabolically stable and displays a favorable pharmacokinetic profile with an elimination half-life of 3.1 h, which could be treated as a promising candidate for further clinical development.
- 4 August 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (16) , 7166-7185
Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide
Protease-activated receptor-1 (PAR1), a G-protein-coupled receptor, plays a critical role in thrombin-mediated platelet aggregation. It is regarded as a promising antithrombosis target that is unlikely to result in bleeding. Here, we describe the synthesis of a series of novel PAR1 antagonists by borrowing the chiral fragment of andrographolide, an easily accessible natural molecule from Andrographis paniculata, to produce natural product/synthesis hybrids. An in vitro PAR1 inhibition assay and an in vivo pharmacokinetic profile led to the identification of compound 39 as the best PAR1 inhibitor. The further in vitro and ex vivo antiplatelet aggregation assays of compound 39 indicated that compound 39 was a potent antiplatelet agent. In addition, this compound is metabolically stable and displays a favorable pharmacokinetic profile with an elimination half-life of 3.1 h, which could be treated as a promising candidate for further clinical development.